-
Mashup Score: 33
Twice-yearly inclisiran provided sustained reductions in LDL cholesterol and PCSK9 concentrations and was well tolerated over 4 years in the extension study. This is the first prospective long-term study to assess repeat hepatic exposure to inclisiran.
Categories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 0Hypertrophic Cardiomyopathy in Review: ESC–HFA 2022 & How to Differentiate HCM From Its Phenocopies - 2 year(s) ago
In this two-part hypertrophic cardiomyopathy video series, Dr Ahmad Masri discusses important cardiomyopathy data that has been presented at the ESC–HFA annual congress 2022 and how
Source: www.radcliffecardiology.comCategories: Cardiologists, Latest HeadlinesTweet
Long-term efficacy and safety of #inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year #OLE of the ORION-1 trial. https://t.co/dz9mSLTNhB